Dr. Roger Tsang
Positions
Clinical Assistant Professor
Cumming School of Medicine, Department of Oncology
Medical Oncologist
Arthur J.E. Child Comprehensive Cancer Centre
Program Chief Medical Information Officer (PCMIO) - Cancer Care
Alberta Health Services
Member
Arnie Charbonneau Cancer Institute
Contact information
Phone number
Office: 587.231.6051
Background
Educational Background
Bachelor of Medical Science (BMSc) , University of Alberta, 2003
Doctor of Medicine (MD) with Special Training in Research , University of Alberta, 2004
Internal Medicine , Fellow of the Royal College of Physicians of Canada (FRCPC), 2008
Medical Oncology , Sub-Specialty Certification, Royal College of Physicians and Surgeons of Canada, 2009
Biography
Dr. Tsang is a medical oncologist at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary. He obtained his MD with Special Training in Research at the University of Alberta, followed by residency training in Internal Medicine and Medical Oncology in Edmonton. He also completed a Translational Oncology research fellowship at UCLA in Los Angeles, California. In 2020, he received an Evidence-Based Medicine teaching award from the Medical Oncology residency training program. He is passionate about health informatics, and the intersection of information technology, data science, and clinical medicine to enhance patient care and improve outcomes through digital innovation. From 2018 to 2025, he served as the Medical Informatics Lead in Medical Oncology for the Calgary Zone, contributing significantly to the implementation and optimization of Alberta Health Services (AHS) Connect Care, Epic Systems' EHR. In 2025, he assumed the inaugural role of Program Chief Medical Information Officer (PCMIO) for Cancer Care, AHS.
Research
Areas of Research
- Breast Cancer
- Neuro-Oncology (CNS Cancers)
- Informatics
- Artificial Intelligence Applications
Dr. Tsang is an active participant in local, cooperative group, and industry-sponsored research studies in breast and central nervous system (CNS) cancers. He is the site PI for Canadian Cancer Trials Group (CCTG) CEC.6 [ALLIANCE N0577], a phase III clinical trial evaluating temozolomide versus PCV chemotherapy in patients with 1p/19q co-deleted gliomas. He is a co-investigator in a phase I/II study evaluating niacin in patients with newly diagnosed glioblastoma. He is the Qualified Investigator (QI) for a study evaluating a novel portable breast imaging device using microwave signals (PI: Fear), and a co-investigator in a study evaluating its use in patients receiving neoadjuvant systemic therapy. He participates in and strongly values interdisciplinary collaborations, particularly in the fields of medtech, informatics, and translational research. He also serves as a physician member on the CCTG Audit and Monitoring Committee, which is tasked with maintaining the integrity, safety, and quality of cancer clinical trials.
Are you the profile owner?
Login to edit.